Literature DB >> 2169368

Effects of isosorbide dinitrate on the pattern of arterial blood flow in healthy human subjects.

C G Caro1, P J Fish, D E Goss, J Halls, M J Lever, K H Parker, A S Clear.   

Abstract

1. Blood velocity measurements have been made in the superficial femoral artery, 10 cm downstream of the common femoral artery bifurcation, in healthy human subjects, using a multi-channel Doppler ultrasound device. 2. In a randomized double-blind protocol, the effects of isosorbide dinitrate were examined during a 2 h period. 3. The changes induced by isosorbide dinitrate include: (i) an increase in the width of the artery and a reduction in brachial arterial blood pressure, implying relaxation of arterial smooth muscle; (ii) an increase in reverse flow and a decrease in time-averaged mean velocity associated with a relatively small decrease of the velocity excursion during the cardiac cycle, implying an increase in flow pulsatility; and (iii) an alteration of the flow pattern both in the core and near the vessel walls.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2169368     DOI: 10.1042/cs0790215

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  3 in total

1.  Influence and interference of isosorbide dinitrate and food intake on superior mesenteric artery impedance in humans.

Authors:  D Voet; S Mareels; M Afschrift; M De Buyzere; E Rietzschel; D Duprez
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

2.  Influence of isosorbide dinitrate on superior mesenteric artery impedance in humans.

Authors:  D Voet; M Afschrift; D Duprez; M De Buyzere; F Barbier
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

3.  Comparison of lisinopril and nitrendipine on the pulsatility index in mild essential arterial hypertension.

Authors:  D Duprez; M De Buyzere; F Brusselmans; A Maas; D L Clement
Journal:  Cardiovasc Drugs Ther       Date:  1992-08       Impact factor: 3.727

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.